UK biotech sector has shrugged off a difficult economic environment with a 44% increase in venture capital investment in the ...

In the Krascedo-1 trial, Roche's KRAS G12C inhibitor divarasib met the company's high expectations, with a head-to-head win ...

First teased earlier this year, the phase 3 CLARITY-Gastric01 study included previously treated patients with locally advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, or ...

Sofe-m was acquired by Lilly as part of its 2023 takeover of French biotech Mablink Bioscience and its PSARLink ADC ...

In the phase 3 OptiTROP-Lung06 study, which was run by Kelun in 455 Chinese patients, sac-TMT reduced the risk of disease ...

VOLGA was conducted in patients with MIBC ineligible or unwilling to take platinum-based chemotherapy, who received PD-L1 inhibitor Imfinzi (durvalumab) before and after surgery to remove the tumour, ...

The full look at the results of the DeLLphi-305 study of Imdelltra (tarlatamab) and Imfinzi (durvalumab) as first-line maintenance therapy for extensive-stage SCLC (ES-SCLC) whose disease had not ...

Nubeqa is a key growth product for Bayer, with sales up around 60% to €1.63 billion in the first half of this year from its ...

Moderna and MSD have shared keenly anticipated results for their melanoma cancer vaccine, ahead of a presentation at ESMO ...

A drug at the heart of Johnson & Johnson's $3 billion takeover of Halda last year, JNJ-6143, has shown promise in an ...

Merck KGaA has reached a deal to acquire UK-based Silence Therapeutics in ​an all-cash, $1.3 billion deal that will boost its ...

Waterhouse is due to take the helm of CSL on 1st February next year, around a year after Paul McKenzie abruptly departed the ...